Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05928104
Other study ID # IRAS 313644
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 12, 2023
Est. completion date January 31, 2024

Study information

Verified date June 2023
Source University of East Anglia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

An increasing number of people are diagnosed with long-term conditions and are prescribed medicines to manage these conditions. Medication reviews (MRs) are used to optimise medicines, improve health outcomes, and decrease medicines related problems. Although medication reviews are widely used in health care settings, there has not been a dramatic change in the the rate at which patients experience poor medicines outcomes such as adverse drug reactions and hospitalisations. This research wants to understand how medication reviews by pharmacists are delivered in GP surgeries and community pharmacies. The research team plans to test a co-designed document, which outlines what pharmacists should do in a MR, in a small number of GP surgeries, on a limited number of patients. Pharmacists and patients who have used this document will be interviewed to understand their thoughts and feelings about the process.


Description:

Approximately 15 million people in England have a long-term condition (LTC) or chronic disease, such as heart disease, asthma, diabetes, for which there is currently no cure. Long-term conditions are mostly managed by medicines with 1.12 billion prescription items dispensed in England in 2019 at a total cost of £9.08 billion. Recent government reports have identified that prescribing too many or inappropriate medicines can lead to more medicines related problems and poor patient outcomes, such as drug interactions, adverse drug reactions, reduced quality of life, and hospitalisations. Medication reviews are used to support patients with their medicines and to reduce the risk of over and inappropriate prescribing. Desired outcomes for medication reviews include optimising medicines, improving health outcomes, and decreasing medicines related problems. It has become more common for medication reviews to be used by doctors, nurses, and pharmacists in the last ten years, but the rate at which patients experience poor medicines outcomes such as adverse drug reactions and hospitalisations because of medicines use has not changed much in this time. Pharmacists are considered to be medicines experts, so many organisations are encouraging them to be involved with the delivery of medication reviews. Pharmacists currently undertake various types of medication reviews in general practitioner (GP) surgeries, Primary Care Networks (PCN), and community pharmacies. When interventions are introduced to address problems such as overprescribing, it is important to better understand how they have been designed and delivered. The Medical Research Council (MRC) has provided guidance on the process evaluation of complex interventions (of which medication reviews are an example). This states that the key steps in evaluating complex interventions are: - Understanding how and what is delivered Understanding how the intervention produces change - Understanding how context affects implementation and outcomes To understand the evidence for pharmacist-led medication reviews, a scoping review was undertaken with the aim of describing the existing, extensive literature in this field. This scoping review identified numerous systematic reviews that included a significant quantity of primary research from a wide range of countries. It concluded that overall evidence for effectiveness for medication reviews is uncertain (no strong evidence for or against their effect on patient outcomes). In addition, it identified that most reviews did not describe in depth what is delivered and how the intervention produces change. Therefore, it is difficult to know, from the existing systematic review literature, which elements of the medication review are likely to benefit the patient and the health service. As a follow-up to this scoping review a systematic review was undertaken to explore what is delivered (the core components of pharmacist-led medication reviews), and whether and how they link to outcomes in different contexts. In addition to extracting data about context, implementation, outcomes, and mechanisms of impact (how intervention produces change), this systematic review also extracted information about actions that affect patients' medicines taking behaviour and implementation strategies (activities that describe how an intervention was delivered). The output from the systematic review was a draft programme theory. A programme theory describes how an intervention is expected to lead to its effects and under what conditions. The programme theory for pharmacist-led medication reviews shows how the intervention may achieve patient and health service outcomes The literature reviews have established what has been reported in previous studies, and the evidence for pharmacist-led medication reviews. The next step is to find out what is happening in practice. The current GP and community pharmacy contracts provide some guidance to the provision of medication reviews. However, these documents lack details on why elements have been included and how they will benefit the patient. Focus groups with patients and practitioner (pharmacists, GPs and practice nurses) were undertaken to establish what is happening is practice and the key uncertainties (unknown or incomplete essential details relating to the content and implementation of medication reviews) are. The results from the focus groups, combined with the outcomes from the systematic review were used to design an optimised, evidence-informed pharmacist-led medication review, with the help of stakeholders, such as pharmacists, patients, and GPs.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date January 31, 2024
Est. primary completion date December 22, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged = 18 years Due for a medication review by the practice pharmacist Effectively communicate in English Provide informed consent Exclusion Criteria: - Have no access to telephone/ internet Recently received a medication review

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Medication review
Pharmacist-led medication review in primary care using a co-designed document

Locations

Country Name City State
United Kingdom North Elmham surgery Dereham Norfolk
United Kingdom Toftwood surgery Dereham Norflok
United Kingdom Sheringham Medical Practice Sheringham Norfolk

Sponsors (1)

Lead Sponsor Collaborator
University of East Anglia

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient feasibility and acceptability Patients will be interviewed to assess their thoughts and feelings after receiving the medication review 3 months
Primary Pharmacist feasibility and acceptability Pharmacists will be interviewed to assess their thoughts and feelings after delivering medication reviews using the service specification 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04722848 - Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL Phase 3
Recruiting NCT05026229 - A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL N/A
Recruiting NCT05024357 - A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL N/A
Recruiting NCT06052813 - A Study of BN104 in the Treatment of Acute Leukemia Phase 1/Phase 2
Recruiting NCT05473910 - A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation Phase 1
Recruiting NCT03884829 - A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS Phase 1
Active, not recruiting NCT03541083 - Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. Phase 2
Recruiting NCT06250959 - RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. Phase 2
Active, not recruiting NCT03751709 - Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL Phase 1
Recruiting NCT04482894 - Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS Phase 2
Recruiting NCT05480904 - Characterizing Sleep Among Long-term Survivors of Childhood Cancer
Completed NCT04357041 - COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being